Hints and tips:
Related Special Reports
...GlaxoSmithKline said its potential new blockbuster shot for respiratory syncytial virus appears to be more effective than rival Pfizer’s vaccine candidate, as the pair compete for a new market protecting...
...GlaxoSmithKline has raised its yearly profit and sales guidance for the second quarter in a row after beating analysts’ expectations for the three months to September....
...GlaxoSmithKline’s chief executive said a shareholder vote in favour of spinning off its consumer healthcare business vindicated the UK drugmaker’s decision to turn down a £50bn takeover offer from Unilever...
...Pharmaceuticals group Sanofi has reported positive results from a Covid-19 booster vaccine that it has developed with GlaxoSmithKline....
...GlaxoSmithKline chief executive Emma Walmsley said the imminent spin-off of the consumer health division Haleon would untangle the UK drugmaker’s complex “Gordian knot” structure and enable her to tackle...
...GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting positive data showing the shot is the first to work in the vulnerable age group for the...
...Sanofi is leading the vaccine development, with GSK contributing its efficacy-enhancing adjuvant....
...GlaxoSmithKline will acquire Boston-based biotech Affinivax in a transaction worth up to $3.3bn, as it seeks to bolster its vaccines business with a new technology....
...Pfizer will sell down its stake in Haleon, its consumer health joint venture with GlaxoSmithKline, after a London listing planned for July 18....
...The below chart is a Factiva global media search for articles about Zantac and cancer for the last five years: And here’s how many of those articles reference either GSK/GlaxoSmithKline or Sanofi, overlaid...
...GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults, after reporting data showing the shot is the first to work in the vulnerable age group for the major...
...The merged word reflects GlaxoSmithKline’s optimism about its soon-to-be demerged consumer business....
...Sanofi developed the vaccine, with GSK providing an adjuvant that boosts its efficacy....
...GlaxoSmithKline is buying Boston-based biotech Affinivax in a transaction worth up to $3.3bn, bolstering its vaccines business with new technology....
...Bumper sales of GlaxoSmithKline’s Covid-19 antibody treatment and a bounce back in demand for its shingles vaccine helped the UK drugmaker beat expectations in the first quarter....
...GlaxoSmithKline has reached an agreement to acquire Sierra Oncology for £1.5bn, as the UK drugmaker seeks to bolster its cancer treatment business ahead of a spin-off of its consumer health division this...
...GlaxoSmithKline has reached an agreement to buy blood cancer specialist Sierra Oncology for £1.5bn as part of plans to strengthen its drug pipeline after pressure from activist investors....
...GlaxoSmithKline’s ViiV Healthcare is “actively negotiating” a voluntary licence on the patents for its injectable HIV prevention drug to make it more widely available in poorer nations, where fewer than...
...Several hundred GlaxoSmithKline workers have voted to go on strike after rejecting a below inflation pay rise, setting the stage for an industrial battle unusual in the pharmaceutical industry....
...GlaxoSmithKline: shingle minded Worried about shingles? GlaxoSmithKline is....
...GlaxoSmithKline’s former head of research and development has been forced to hand back $3.9mn in cash to the UK drugmaker, after being accused of sexual harassment and inappropriate conduct towards an employee...
...GSK forecasts that sales will rise between 5 and 7 per cent and adjusted operating profits will grow between 12 and 14 per cent in 2022....
International Edition